121 results about "Vancomycinum" patented technology

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

The invention discloses a VEGF and vancomycin-supported multilayer local slow release microsphere preparation with sodium alginate and chitosan as a carrier, a preparation method of the microsphere preparation, and an application of the microsphere preparation in the preparation of medicines for treating bone defects, bone tissue regeneration and wound healing, and belongs to the technical field of medicine slow release microspheres. In the invention, a core sphere is prepared through an instillation process, and other multilayer microspheres are prepared according to a positive and negative charge attraction and layer-by-layer self assembling principle. Sodium alginate and chitosan are natural polymer polysaccharides, chitosan is a polycation polymer material, and the side chain structure of chitosan contains a large number of free amino groups; and sodium alginate is a polyanion material, the molecular side chain of sodium alginate contains a large number of carboxyl groups, sodium alginate and chitosan undergo a complexing reaction through attraction of positive and negative charges, and the core-shell multilayer slow release medicine multilayer sphere is formed by sequentially wrapping according to the layer-by-layer self assembling principle, so multilayer slow release microsphere preparation can promote local angiogenesis, improve blood circulation and control local infection.

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

The invention relates to the field of biological medicine, in particular to an application of Rakicidins compounds in resistance to clinical pathogenic anaerobic bacteria. Pharmacodynamic experiments indicate that the Rakicidins compounds have good resistant effect on the clinical pathogenic anaerobic bacteria and have the resistant effect on vancomycin enterococcus infection diseases. The Rakicidins compounds can be used for treating diarrhea, enteritis, alimentary infection, oral infection or skin acne caused by clostridium difficile as well as diseases such as urinary tract infection, or skin soft-tissue infection and the like.

The invention relates to the field of drugs, in particular to a detection method for simultaneously determining content of vancomycin and tobramycin in tissue drainage liquid. A method for simultaneously determining content of vancomycin and tobramycin in tissue drainage liquid through an ultrahigh performance liquid chromatography-triple quadrupole mass spectrometry (UPLC-TQD) coupling techniquecomprises the following steps of: 1) preparing reference samples; 2) preparing internal standard solution; 3) preparing sample solution; 4) preparing mobile-phase solution; 5) setting chromatographicconditions; 6) optimizing mass spectrometric conditions; 7) determining the samples; 8) preparing gradient-concentration reference sample solution; 9) preparing a standard curve; and 10) analyzing and computing data. The method has the characteristics that: 1) the method is advanced; 2) the method is rapid and high-efficiency the loss is low; and 3) the clinical application prospect and the effect are good.

The invention belongs to the field of antibiotic preparation technologies, and more specifically relates to a preparation method of vancomycin with high purity. The preparation method comprises following steps: a destaining solution of vancomycin is subjected to column chromatography in a chromatography media, wherein the chromatography media is UniPMM50CAR, the NH4HCO3 mass concentration of a mobile phase of column chromatography is 0.2 to 0.7%; when absorbance rises to 40 at a detection wavelength of 280nm, chromatography liquids are collected segment by segment, the pH value of the chromatography liquids is adjusted to 3.0 to 3.5, the chromatography liquids are preserved under 4 DEG C, and the collected chromatography liquids are mixed. Bubbles in the chromatographic column caused by degradation of carbonate are not likely to generate by using the preparation method. The preparation method is capable of increasing stage number and separation efficiency. The appearance of the obtained vancomycin is improved significantly, purity is as high as 99%, and the vancomycin can be taken orally or by injection.

A method for producing vancomycin hydrochloride by utilizing a vancomycin fermentation broth comprises pretreatment of the vancomycin fermentation broth, inorganic ceramic membrane filtration, ultrafiltration, nanofiltration, crystal water-washing, acid-base neutralization and vacuum freeze drying. The method helps to realize the stable efficient production of vancomycin hydrochloride. Also the method helps to improve the extraction yield, shorten the production period, reduce the cost and improve the yield of vancomycin hydrochloride.

The invention provides a processing method of vancomycin fermentation residue. The invention makes use of vancomycin fermentation residue as a sole culture medium, and the solid state culture method is adopted under the proper conditions for culturing yeast. The obtained yeast culture dry powder does not contain vancomycin residue after the culture and proper drying and smashing. Thus, the method not only solves the vancomycin residue problem in vancomycin fermentation residue and realizes the harm-free processing, but also can effectively cultures yeast and obtains a great deal of yeast protein with application value.

The invention discloses Myrtucommulone R and application thereof in preparing antibacterial drug. Structure of phloroglucinol tripolymer Myrtucommulone R is shown as a formula I, and Myrtucommulone R is a new natural product. The compound even at low concentration has remarkable antibacterial activity to staphylococcus aureus, methicillin-resistant staphylococcus aureus, vancomycin-intermediate-resistant staphylococcus aureus and vancomycin-resistant enterococcus faecium and has quite low toxicity to eukaryocytes, indicating that the compound has good medicinal prospect and can be applied to preparing an antibacterial drug preparation. The antibacterial drug preparation contains Myrtucommulone R and the balance of medicinal auxiliary materials or other compatible drugs. The antibacterial drug preparation includes various clinical drug dosage forms.

The invention discloses novel effective cerecidin and an application thereof. The cerecidin disclosed by the invention is a modified polypeptide. A synthetic method of the cerecidin disclosed by the invention is simpler compared with the conventional method. Meanwhile, the synthesized cerecidin has relatively high antibacterial activity, the antibacterial effect of the cerecidin for resisting vancomycin enterococcus faecalis V583(VRE) is better than that of nisin, and under a relatively wide pH condition and a high temperature, the cerecidin is relatively stable.

The invention discloses a universal type multi-signal output biosensor, as well as a preparation method and application thereof. The universal type multi-signal output biosensor comprises two parts: a transcyclooctene modified vancomycin derivative used as a recognition molecule and functionalized gold and silver compound nanoparticles used as a signal conversion element, wherein the amino activated locus of the vancomycin molecule is covalently coupled with transcyclooctene; the gold and silver compound nanoparticles adopt silver shell-gold core compound nanoparticles; the surfaces of the gold and silver compound nanoparticles are simultaneously modified with a disulfide bond-containing tetrazine compound and a Raman microprobe molecule. The universal type multi-signal output biosensor can be applied to detection of Gram-positive pathogens, has the advantages of being high in efficiency, low in external environment influence, wide-spectral in targets and the like, and can meet the requirement of actual production and living.

Immunoassay reagents, methods and test kits for the specific quantification of vancomycin in a test sample are disclosed. The reagent comprises antibodies prepared with immunogens of FIG. 6 wherein P is an immunogenic carrier material and X is a linking moiety.

Also described is the synthesis of labeled reagents of FIG. 8 wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and X is a linking moiety.

Pre-mixed, ready-to-use injectable compositions possess certain advantages such as convenience and ease of use as compared to an ampule formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations. Pre-mixed, ready-to-use Vancomycin injectable preparations though marketed have numbers of disadvantages which makes its handling and use difficult. The present invention therefore provides pre-mixed, ready-to-use injectable formulations of Vancomycin which eliminates disadvantages and difficulties of the marketed product and at the same time maintains desired stability for prolonged time.

The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.

The invention is directed to methods of converting a carboxylic acid group in a compound, via a redox active ester, to a corresponding boronic ester by treatment with bis(pinacolato)diboron-alkyllithium complex in the presence of a ligand, a Ni(ll) salt or a copper salt, and an Mg(ll) salt, in the presence of an alkyllithium or a lithium hydroxide or alkoxide salt. The product pinacolato boronateester can be cleaved to provide a boronic acid. The invention is also directed to methods of preparing various compounds of medical value comprising boronic acid groups, and to novel boronic-acid containing compounds of medicinal value, including an atorvastatin boronic acid analog, a vancomycin aglycone boronic acid analog, and boronic acid containing elastase inhibitors mCBK319, mCBK320, mCBK323, and RPX-7009.

The invention particularly relates to a vancomycin-modified black phosphorus quantum dot antibacterial agent and a preparation method and application thereof. Development of antibacterial drugs has the defects of long period and high cost, and the formation speed of strain drug resistance exceeds the research and development speed of drugs. In order to provide a drug with better antibacterial effect and reduced drug resistance, vancomycin modified black phosphorus quantum dots are adopted as an antibacterial active component, and vancomycin is bonded to the surfaces of the black phosphorus quantum dots through covalent bonds. Studies prove that the vancomycin-modified black phosphorus quantum dot has significantly improved antibacterial properties, is expected to become a first-line activecomponent of clinical antibacterial drugs, and has good development significance.

The invention, belonging to the technical field of pharmaceutical chemistry and medicine, particularly relates to a novel vancomycin or demethyl vancomycin analogue of formula (1) and medicinal uses thereof. By carrying out tests of in vivo inhibition of clostridium difficile on the compound of formula (1), the results show that the compound has significantly higher antibacterial activity on clostridium difficile than vancomycin or demethyl vancomycin in the prior art, and the compound disclosed herein can be prepared into safe, effective and novel vancomycin or demethyl vancomycin analogues, pharmaceutical compositions of a medicinal carrier and various preparations. The novel vancomycin or demethyl vancomycin analogue disclosed herein can be used for preparing anti-infection medicines, especially medicines for resisting the infection of clostridium difficile.

The invention belongs to the technical field of drug concentration monitoring, and relates to a method for simultaneously determining concentrations of vancomycin and a crystalline degradation productCDP-1 in human serum by LC-MS/MS. According to the method, norvancomycin is used as an internal standard, formic acid is used for acidifying serum, quantitative acetonitrile precipitated protein is added, acetonitrile and formic acid water are used as mobile phases, and the concentrations of human serum vancomycin and CDP-1 are determined through an LC-MS/MS method. According to the method, the sampling amount is small, and pretreatment is simple and rapid. The method can be used for determining the concentrations of vancomycin and degradation products CDP-1 in serum samples of conventional clinical patients. Particularly, different degrees of CDP-1 generated after hemodialysis of patients with renal insufficiency can be quantified, so that the concentration of the antibacterial active ingredient vancomycin is reduced, an individualized vancomycin dosing scheme can be made and adjusted clinically, the clinical curative effect and the bacterial clearance rate can be improved, the generation of bacterial drug resistance is reduced, and toxic and side effects such as renal toxicity and the like are reduced.

The invention discloses a chlorine dioxide nano-zinc disinfection and bacteriostasis solution, which comprises the following components in parts by weight: 10-30 parts of chlorine dioxide, 5-15 partsof nano-zinc, 2-6 parts of sodium bicarbonate, 2-6 parts of potassium permanganate, 3-6 parts of a stabilizer, 5 parts of penicillin, 5 parts of vancomycin, 2-6 parts of dandelion juice and 100 partsof deionized water. The chlorine dioxide nano-zinc disinfection and bacteriostasis solution disclosed by the invention has a remarkable purification assisting effect on various harmful strains and microorganisms in water resources, and can be used for effectively purifying a water body, killing harmful substances in the water and preventing the generation and propagation dangers of infectious diseases such as hand-foot-and-mouth diseases on a large scale; and the solution is safe and harmless to a human body, simple in preparation process and relatively low in cost, and can be produced on a large scale.